<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <akn:act name="dc-code">
    <akn:meta>
      <akn:identification source="#cosilico">
        <akn:FRBRWork>
          <akn:FRBRuri value="/akn/us-dc/code/7-1305.06c"/>
          <akn:FRBRdate date="2025-12-31" name="retrieval"/>
          <akn:FRBRauthor href="#dc-council"/>
          <akn:FRBRcountry value="us-dc"/>
        </akn:FRBRWork>
        <akn:FRBRExpression>
          <akn:FRBRuri value="/akn/us-dc/code/7-1305.06c/eng@2025"/>
          <akn:FRBRdate date="2025-12-31"/>
          <akn:FRBRauthor href="#cosilico"/>
          <akn:FRBRlanguage language="en"/>
        </akn:FRBRExpression>
      </akn:identification>
    </akn:meta>
    <akn:body>
      <akn:section eId="sec_7_1305_06c">
        <akn:num>7-1305.06c</akn:num>
        <akn:heading>Psychotropic medication review.</akn:heading>
<akn:subsection eId="subsec_7-1305_06c_a">
      <akn:num>(a)</akn:num>
      <akn:content><akn:p>By April 15, 2009, the DDS shall complete a psychotropic medication review for all individuals served by DDS.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_b">
      <akn:num>(b)</akn:num>
      <akn:content><akn:p>By October 17, 2008, the DDS shall establish written procedures, which shall include timelines and shall identify responsible entities or individuals, for promptly implementing the recommendations for each individual identified by the psychotropic medication review.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_c">
      <akn:num>(c)</akn:num>
      <akn:content><akn:p>The psychotropic medication review shall be conducted by a review team that includes professionals with expertise in the prescription, use, and side effects of psychotropic medications as therapy for individuals who have been dually diagnosed with intellectual disabilities and mental illness.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_d">
      <akn:num>(d)</akn:num>
      <akn:content><akn:p>DDS shall establish in writing:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_e">
      <akn:num>(e)</akn:num>
      <akn:content><akn:p>The review team shall complete the initial administrative review of psychotropic medications. The initial administrative review of psychotropic medications shall determine, at minimum, for each individual served by DDS:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_f">
      <akn:num>(f)</akn:num>
      <akn:content><akn:p>The review team shall conduct a clinical review of psychotropic medications when the initial administrative review meets the review team’s criteria indicating that a detailed clinical review of the individual’s psychotropic medication is warranted. The clinical review shall seek to determine the clinical appropriateness of each prescribed psychotropic medication and the potential for alternative approaches. The clinical review shall include, at a minimum, interviews with the individual, the prescribing professional, and the individual’s residential and day service providers, if any.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_g">
      <akn:num>(g)</akn:num>
      <akn:content><akn:p>By no later than 30 days after completing a psychotropic medication review of an individual, the review team shall issue a written report, which shall include recommendations for:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06c_h">
      <akn:num>(h)</akn:num>
      <akn:content><akn:p>A copy of the written report of the review team shall be appended to the individual’s individual habilitation plan and shall be provided to:</akn:p></akn:content>
    </akn:subsection>
      </akn:section>
    </akn:body>
  </akn:act>
</akn:akomaNtoso>
